Scyllitol

Scyllitol

SCHEMBL581992

CCO.O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Scyllitol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.60
TSHR P16473 1/20 0.60
LMNA P02545 1/20 0.50
APP P05067 1/20 0.50
MGAM O43451 8/20 0.44
GAA P10253 2/20 0.44
SI P14410 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44
FUCA1 P04066 7/20 0.43
GLA P06280 2/20 0.39
GANC Q8TET4 2/20 0.39
FUCA2 Q9BTY2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Inositol SCHEMBL5039565 1.00 ALDH1A1 (0.60) ALDH1A1TSHRLMNAAPPMGAM
Inositol SCHEMBL3835408 0.84 LMNA (0.56) ALDH1A1TSHRLMNAAPPMGAM
Alcohol SCHEMBL3721594 0.84
Alcohol SCHEMBL28808624 0.78
Alcohol SCHEMBL17770701 0.78
Alcohol SCHEMBL9461084 0.78 TSHR (1.00) ALDH1A1TSHRLMNA
Alcohol SCHEMBL2464657 0.78 TSHR (1.00) ALDH1A1TSHRLMNA
Alcohol SCHEMBL54946 0.78
Alcohol SCHEMBL6910520 0.78 TSHR (1.00) ALDH1A1TSHRLMNA
Alcohol SCHEMBL29975647 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9815770-B2 Inhibitors of cognitive decline COGNITION THERAPEUTICS, INC. (US) 2017-11-14 US disclosed
EP-2670402-B1 ISOLATED COMPOUNDS FROM TURMERIC OIL AND METHODS OF USE COGNITION THERAPEUTICS INC (US) 2017-09-20 EP disclosed
US-20170049723-A1 ISOLATED COMPOUNDS FROM TURMERIC OIL AND METHODS OF USE COGNITION THERAPEUTICS, INC. 2017-02-23 US disclosed
US-20160355458-A1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS, INC. 2016-12-08 US disclosed
US-9499462-B2 Isolated compounds from turmeric oil and methods of use COGNITION THERAPEUTICS, INC. (US) 2016-11-22 US disclosed
US-9365491-B2 Inhibitors of cognitive decline COGNITION THERAPEUTICS, INC. (US) 2016-06-14 US disclosed
US-20160137588-A1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS, INC. 2016-05-19 US disclosed
US-9192585-B2 Inhibitors of cognitive decline COGNITION THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
EP-2458983-B1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS INC (US) 2015-07-08 EP disclosed
EP-2416795-B1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS INC (US) 2015-06-03 EP disclosed
WO-2012106426-A1 ISOLATED COMPOUNDS FROM TURMERIC OIL AND METHODS OF USE COGNITION THERAPEUTICS, INC. (US) 2012-08-09 WO disclosed
EP-2458983-A1 INHIBITORS OF COGNITIVE DECLINE Cognition Therapeutics, Inc. (US) 2012-06-06 EP disclosed
US-20120129945-A1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS, INC. (US) 2012-05-24 US disclosed
US-20120095105-A1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS, INC. (US) 2012-04-19 US disclosed
EP-2416795-A1 Inhibitors of cognitive decline Cognition Therapeutics, Inc. (US) 2012-02-15 EP disclosed
WO-2011143587-A1 NITRO FATTY ACIDS - NEUROPROTECTION AND/OR INHIBITION OF COGNITIVE DECLINE NITROMEGA CORP. (US) 2011-11-17 WO disclosed
US-20110280852-A1 NITRO FATTY ACIDS - NEUROPROTECTION AND/OR INHIBITION OF COGNITIVE DECLINE NITROMEGA CORP. (US) 2011-11-17 US disclosed
WO-2011106785-A2 METHODS OF IDENTIFYING AGENTS EFFECTIVE TO TREAT COGNITIVE DECLINE AND DISEASES ASSOCIATED THEREWITH COGNITION THERAPEUTICS, INC. (US) 2011-09-01 WO disclosed
WO-2011014880-A1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS, INC. (US) 2011-02-03 WO disclosed
WO-2010118055-A1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS, INC. (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095105-A1 INHIBITORS OF COGNITIVE DECLINE PSEN2, ACHE, MAPT ALDH1A1 3071/4885TSHR 4113/4885LMNA 3447/4885
US-20120129945-A1 INHIBITORS OF COGNITIVE DECLINE PSEN2, ACHE, MAPT ALDH1A1 3071/4885TSHR 4113/4885LMNA 3447/4885
US-20160355458-A1 INHIBITORS OF COGNITIVE DECLINE PSEN2, ACHE, MAPT ALDH1A1 3071/4885TSHR 4113/4885LMNA 3447/4885
US-20170049723-A1 ISOLATED COMPOUNDS FROM TURMERIC OIL AND METHODS OF USE APP, MAPT, PSEN1 ALDH1A1 3105/4885TSHR 4146/4885LMNA 3145/4885
US-20110280852-A1 NITRO FATTY ACIDS - NEUROPROTECTION AND/OR INHIBITION OF COGNITIVE DECLINE NLN, SMN1; SMN2, CASP10 ALDH1A1 1468/4885TSHR 4597/4885LMNA 730/4885
US-20160137588-A1 INHIBITORS OF COGNITIVE DECLINE PSEN2, ACHE, MAPT ALDH1A1 3071/4885TSHR 4113/4885LMNA 3447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.